Butorphanol-mediated antinociception in mice: Partial agonist effects and Mu receptor involvement

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1253-1261

  Garner, H R ^a,b   Burke, Timothy F ^a,c   Lawhorn, C David ^a,d   Stoner, Joanne M ^a   Wessinger, William D ^a,e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Astra Merck Inc   (United States)

^d Dept of Pharmacology and Toxicology ^*  (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; BETA FUNALTREXAMINE; BUTORPHANOL TARTRATE; FENTANYL; KAPPA OPIATE RECEPTOR; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, OPIOID; ANIMALS; BUTORPHANOL; MALE; MICE; MORPHINE; NALTREXONE; PYRROLIDINES; RECEPTORS, OPIOID, MU;

EID: 0030931722     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. ARUNLAKSHANA, O. AND SCHILD, H. O.: Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14: 48-58, 1959.
2. 2 analysis. J. Pharmacol. Exp. Ther. 243: 591-597, 1987.
3. 2 response and ventilation after fentanyl anesthesia. Anesth. Analg. 66: 517-522, 1987.
4. BROADBEAR, J. H., NEGUS, S. S., BUTELMAN, E. R., DECOSTA, B. R. AND WOODS, J. H.: Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay. Psychopharmacology 115: 311-319, 1994.
5. BROWN, G. R.: Stadol dependence: Another case. JAMA 254: 910, 1985.
6. BUTELMAN, E. R., WINGER, G., ZERNIG, G. AND WOODS, J. H.: Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys. J. Pharmacol. Exp. Ther. 272: 845-853, 1995.
7. CHEN, J.-C., SMITH, E. R., CAHILL, M., COHEN, R. AND FISHMAN, J. B.: The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 52: 389-396, 1992.
8. D'AMOUR, F. E. AND SMITH, D. L.: A method for determining loss of pain sensation. J Pharmacol. Exp. Ther. 72: 74-79, 1941.
9. DYKSTRA, L. A.: Behavioral and pharmacological factors in opioid analgesia. In Behavioral Pharmacology: The Current Status, ed. by L. S. Seiden and R. L. Balster, pp. 111-129, Alan R. Liss, New York, 1985.
10. DYKSTRA, L. A.: Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey. J. Pharmacol. Exp. Ther. 254: 245-252, 1990.
11. 2 analysis. In Transduction Mechanisms of Drug Stimuli, ed. by F. C. Colpaert and R. L. Balster, pp. 107-121, Springer-Verlag, Berlin, 1988.
12. DYKSTRA, L. A., GMEREK, D. E., WINGER, G. AND WOODS, J. H.: Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242: 413-420, 1987a.
13. DYKSTRA, L. A., GMEREK, D. E., WINGER, G. AND WOODS, J. H.: Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and β-funaltrexamine. J. Pharmacol. Exp. Ther. 242: 421-427, 1987b.
14. EVANS, W. S., BOWEN, J. N., GIORDANO, F. L. AND CLARK, B.: A case of Stadol dependence. JAMA 253: 2191-2192, 1985.
15. FENG, Y. Z., TSENG, Y. T., JAW, S. R., HOSKINS, B. AND HO, I. K.: Tolerance development to butorphanol: Comparison with morphine. Pharmacol. Biochem. Behav. 49: 649-655, 1994.
16. HARRIS, R. A.: Interactions between narcotic agonists, partial agonists and antagonists evaluated by schedule-controlled behavior. J. Pharmacol. Exp. Ther. 213: 497-503, 1980.
17. HORAN, P., DECOSTA, B. R., RICE, K. C. AND PORRECA, F.: Differential antagonism of U69,593-and bremazocine-induced antinociception by (-)-UPHIT: Evidence for kappa opioid receptor multiplicity in mice. J. Pharmacol. Exp. Ther. 257: 1154-1161, 1991.
18. HORAN, P. J. AND HO, I. K: Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol. Biochem. Behav. 34: 847-854, 1989.
19. HORAN, P. J. AND HO, I. K.: The physical dependence liability of butorphanol: A comparative study with morphine. Eur. J. Pharmacol. 203: 387-391, 1991.
20. HOUDE, R. W.: Analgesic effectiveness of the narcotic agonist-antagonists. Br. J. Clin. Pharmacol. 7: 297S-308S, 1979.
21. KENAKIN, T. P.: Pharmacologic Analysis of Drug-Receptor Interaction, Raven Press, New York, 1987.
22. LAWHORN, C. D. AND BROWN, R. E., JR.: Epidural morphine with butorphanol in pediatric patients. J. Clin. Anesth. 6: 91-94, 1994.
23. LAWHORN, C. D., MCNITT, J. D., FIBUCH, E. E., JOYCE, J. T. AND LEADLEY, R. J., JR.: Epidural morphine with butorphanol for postoperative analgesia after cesarean delivery. Anesth. Analges. 72: 53-57, 1991.
24. LEANDER, J. D.: Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ-opioid receptor. Eur. J. Pharmacol. 86: 467-470, 1983a.
25. LEANDER, J. D.: A kappa opioid effect: Increased urination in the rat. J. Pharmacol. Exp. Ther. 224: 89-94, 1983b.
26. MILLER, L., SHAW, J. S. AND WHITING, E. M.: The contribution of intrinsic activity to the action of opioids in vitro. Br. J. Pharmacol. 87: 595-601, 1986.
27. MORGAN, D. AND PICKER, M.: Contribution of individual differences to discriminative stimulus, antinociceptive, and rate decreasing effects of opioids. Importance of the drugs intrinsic efficacy at the mu receptor. Behav. Pharmacol. 7: 261-275, 1996.
28. NEGUS, S. S., BURKE, T. F., MEDZIHRADSKY, F. AND WOODS, J. H.: Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J. Pharmacol. Exp. Ther. 267: 896-903, 1993.
29. O'CALLAGHAN, J. P. AND HOLTZMAN, S. G.: Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J. Pharmacol. Exp. Ther. 192: 497-505, 1975.
30. PICKER, M. J., NEGUS, S. S. AND CRAFT, R. M.: Butorphanol's efficacy at mu and kappa opioid receptors: Inferences based on schedule-controlled behavior of nontolerant and morphine-tolerant rats and on the responding of rate under a drug discrimination procedure. Pharmacol. Biochem. Behav. 36: 563-568, 1990.
31. PITTS, R. C., WEST, J. P., MORGAN, D., DYKSTRA, L. A. AND PICKER, M. J.: Opioids and rate of positively reinforced behavior: Differential antagonism by naltrexone. Behav. Pharmacol. 7: 205-215, 1996.
32. PORRECA, F., MOSBERG, H. I., HURST, R., HRUBY, V. J. AND BURKS, T. F.: Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J. Pharmacol. Exp. Ther. 230: 341-348, 1984.
33. PORTOGHESE, P. S., LIPKOWSKI, A. W. AND TAKEMORI, A. E.: Binaltorphimine and nor-binaltorphimine: Potent and selective κ-opioid receptor antagonists. Life Sci. 40: 1287-1292, 1987.
34. PORTOGHESE, P. S., SULTANA, M. AND TAKEMORI, A. E.: Naltrindole, a highly selective and potent non-peptide δ-opioid receptor antagonist. Eur. J. Pharmacol. 146: 185-186, 1988.
35. PRESTON, K. L. AND BIGELOW, G. E.: Drug discrimination assessment of agonist-antagonist opioids in humans: A three-choice saline-hydromorphonebutorphanol procedure. J. Pharmacol. Exp. Ther. 271: 48-60, 1994.
36. RUFFOLO, R. R.: Important concepts of receptor theory. J. Auton. Pharmacol. 2: 277-295, 1982.
37. SHANNON, H. E., CONE, E. J. AND GORODETZKY, C. W.; Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: Quantitative antagonism by naloxone. J. Pharmacol. Exp. Ther. 229: 768-774, 1986.
38. SHYU, W. C., PITTMAN, K. A., ROBINSON, D. AND BARBHAIYA, R. H.: Multiple-dose phase I study of transnasal butorphanol. Clin. Pharmacol. Ther. 54: 34-41, 1993.
39. SMITH, M. A. AND PICKER, M. J.: Examination of the kappa agonist and antagonist properties of opioids in the rat drug discrimination procedure: Influence of training dose and intrinsic efficacy. Behav. Pharmacol. 6: 703-717, 1995.
40. SMITH, S. G. AND DAVIS, W. M.: Nonmedical use of butorphanol and diphenhydramine. JAMA 252: 1010, 1984.
41. SOFUOGLU, M., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257: 676-680, 1991.
42. SPANAGEL, R., ALMEIDA, O. F. X. AND SHIPPENBERG, T. S.: Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes. Eur. J. Pharmacol. 264: 157-162, 1994.
43. TAKEMORI, A. E.: Determination of pharmacological constants: Use of narcotic antagonists to characterize analgesic receptors. In Narcotic Antagonists, ed. by M. C. Braude, L. S. Harris, E. L. May, J. P. Smith and J. E. Villarreal. Advances in Biochemical Psychopharmacology, Vol. 8, pp. 335-344, Raven Press, New York, 1974.
44. TAKEMORI, A. E., LARSON, D. L. AND PORTOGHESE, P. S.: The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur. J. Pharmacol. 76: 445-451, 1981.
45. TAKEMORI, A. E. AND PORTOGHESE, P. S.: Comparative antagonism by naltrexone and naloxone of μ, κ, and δ agonists. Eur. J. Pharmacol. 104: 101-104, 1984.
46. TALBERT, R. L., PETERS, J. I., SORRELS, S. C. AND SIMMONS, R. S.: Respiratory effects of high-dose butorphanol. Acute Care 12: (suppl. 1) 47-56, 1988.
47. 2 and receptor differentiation: A statistical analysis of competitive antagonism. Life Sci. 25: 637-654, 1979.
48. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs, 2nd ed., Springer-Verlag, New York, 1987.
49. UPTON, N., SEWELL, R. D. E. AND SPENCER, P. S. J.: Differentiation of potent μ-and κ-opiate agonists using heat and pressure antinociceptive profiles and combined potency analysis. Eur. J. Pharmacol. 78: 421-429, 1982.
50. VOGELSANG, J. AND HAYES, S. R.: Butorphanol tartrate (Stadol): A review. J. Post Anesth. Nursing 6: 129-135, 1991.
51. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J. Pharmacol. Exp. Ther. 271: 959-968, 1994.
52. WARD, S. J., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J. Pharmacol. Exp. Ther. 220: 494-498, 1982.
53. WARD, S. J. AND TAKEMORI, A. E.: Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J. Pharmacol. Exp. Ther. 224: 525-530, 1983.
54. WESSINGER, W. D. AND MCMILLAN, D. E.: Quantitative analysis of naloxone antagonism of the discriminative stimulus properties of morphine in the pigeon. Pharmacol. Biochem. Behav. 25: 209-214, 1986.
55. YOUNG, A. M., MASAKI, M. A. AND GEULA, C.: Discriminative stimulus effects of morphine: Effects of training dose on agonist and antagonist effects of mu opioids. J. Pharmacol. Exp. Ther. 261: 246-257, 1992.
56. ZIMMERMAN, D. M., LEANDER, J. D., REEL, J. K. AND HYNES, M. D.: Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J. Pharmacol. Exp. Ther. 241: 374-378, 1987.